[1]
Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(1), 7-30.
[2]
Ruberte, A.C.; Plano, D.; Encío, I.; Aydillo, C.; Sharma, A.K.; Sanmartín, C. Novel selenadiazole derivatives as selective antitumor and radical scavenging agents. Eur. J. Med. Chem., 2018, 5(157), 14-27.
[3]
Liu, Z.; Sun, Q.; Wang, X. PLK1, a potential target for cancer therapy. Transl. Oncol., 2017, 10(1), 22-32.
[4]
Wang, Y.; Wu, L.; Yao, Y.; Lu, G.; Xu, L.; Zhou, J. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. Cancer Lett., 2018, 436, 1-9.
[5]
Lee, J.K.; Ha, G.H.; Kim, H.S.; Lee, C.W. Oncogenic potential of BEX4 is conferred by Polo-like kinase 1-mediated phosphorylation. Exp. Mol. Med., 2018, 50(10), 138.
[6]
Chen, Z.; Chai, Y.; Zhao, T.; Li, P.; Zhao, L.; He, F.; Lang, Y.; Qin, J.; Ju, H. Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells. J. Cell. Physiol., 2018, 234(5), 5904-5914.
[7]
Wang, N.N.; Li, Z.H.; Zhao, H.; Tao, Y.F.; Xu, L.X.; Lu, J.; Cao, L.; Du, X.J.; Sun, L.C.; Zhao, W.L.; Xiao, P.F.; Fang, F.; Su, G.H.; Li, Y.H.; Li, G.; Li, Y.P.; Xu, Y.Y.; Zhou, H.T.; Wu, Y.; Jin, M.F.; Liu, L.; Ni, J.; Wang, J.; Hu, S.Y.; Zhu, X.M.; Feng, X.; Pan, J. Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells. Int. J. Mol. Sci., 2015, 16(1), 1266-1292.
[8]
Noor, A.; Umelo, I.A.; Kronenberger, P.; Giron, P.; De Vlieghere, E.; De Wever, O.; Teugels, E.; De Grève, J. Targeting Polo-like kinase 1 and TRAIL enhances apoptosis in non-small cell lung cancer. Oncotarget, 2018, 9(47), 28731-28744.
[9]
Dang, S.C.; Fan, Y.Y.; Cui, L.; Chen, J.X.; Qu, J.G.; Gu, M. PLK1 as a potential prognostic marker of gastric cancer through MEK-ER K pathway on PDTX models. OncoTargets Ther., 2018, 11, 6239-6247.
[10]
Delacour, Q.; Gavet, O. Re-investigating PLK1 inhibitors as antimitotic agents. Mol. Cell. Oncol., 2017, 4(6)e1356430
[11]
Lian, G.; Li, L.; Shi, Y.; Jing, C.; Liu, J.; Guo, X.; Zhang, Q.; Dai, T.; Ye, F.; Wang, Y.; Chen, M. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells. Int. J. Oncol., 2018, 52(3), 804-814.
[12]
Ferrarotto, R.; Goonatilake, R.; Yoo, S.Y.; Tong, P.; Giri, U.; Peng, S.; Minna, J.; Girard, L.; Wang, Y.; Wang, L.; Li, L.; Diao, L.; Peng, D.H.; Gibbons, D.L.; Glisson, B.S.; Heymach, J.V.; Wang, J.; Byers, L.A.; Johnson, F.M. Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer. Clin. Cancer Res., 2016, 22(7), 1674-1686.
[13]
Hikichi, Y.; Honda, K.; Hikami, K.; Miyashita, H.; Kaieda, I.; Murai, S.; Uchiyama, N.; Hasegawa, M.; Kawamoto, T.; Sato, T.; Ichikawa, T.; Cao, S.; Nie, Z.; Zhang, L.; Yang, J.; Kuida, K.; Kupperman, E. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol. Cancer Ther., 2012, 11(3), 700-709.
[14]
Valsasina, B.; Beria, I.; Alli, C.; Alzani, R.; Avanzi, N.; Ballinari, D.; Cappella, P.; Caruso, M.; Casolaro, A.; Ciavolella, A.; Cucchi, U.; De Ponti, A.; Felder, E.; Fiorentini, F.; Galvani, A.; Gianellini, L.M.; Giorgini, M.L.; Isacchi, A.; Lansen, J.; Pesenti, E.; Rizzi, S.; Rocchetti, M.; Sola, F. NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies. Mol. Cancer Ther., 2012, 11(4), 1006-1016.
[15]
Oliveira, J.C.; Pezuk, J.A.; Brassesco, M.S.; Morales, A.G.; Queiroz, R.G.; Scrideli, C.A.; Tone, L.G. PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer, 2014, 61(7), 1227-1231.
[16]
Ikezoe, T.; Yang, J.; Nishioka, C.; Takezaki, Y.; Tasaka, T.; Togitani, K.; Koeffler, H.P.; Yokoyama, A. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia, 2009, 23(9), 1554-1576.
[17]
Chen, S.; Bartkovitz, D.; Cai, J.; Chen, Y.; Chen, Z.; Chu, X.J.; Le, K.; Le, N.T.; Luk, K.C.; Mischke, S.; Naderi-Oboodi, G.; Boylan, J.F.; Nevins, T.; Qing, W.; Chen, Y.; Wovkulich, P.M. Identification of novel, potent and selective inhibitors of Polo-like kinase 1. Bioorg. Med. Chem. Lett., 2012, 22(2), 1247-1250.
[18]
Goroshchuk, O.; Kolosenko, I.; Vidarsdottir, L.; Azimi, A.; Palm-Apergi, C. Polo-like kinases and acute leukemia. Oncogene, 2019, 38(1), 1-16.
[19]
He, Z.; Deng, W.; Jiang, B.; Liu, S.; Tang, M.; Liu, Y.; Zhang, J. Hsa-let-7b inhibits cell proliferation by targeting PLK1 in HCC. Gene, 2018, 673, 46-55.
[20]
Raab, M.; Sanhaji, M.; Matthess, Y.; Hörlin, A.; Lorenz, I.; Dötsch, C.; Habbe, N.; Waidmann, O.; Kurunci-Csacsko, E.; Firestein, R.; Becker, S.; Strebhardt, K. PLK1 has tumor-suppressive potential in APC-Truncated colon cancer cells. Nat. Commun., 2018, 9(1), 1-17.
[21]
Pajtler, K.W.; Sadowski, N.; Ackermann, S.; Althoff, K.; Schonbeck, K.; Batzke, K.; Schäfers, S.; Odersky, A.; Heukamp, L.; Astrahantseff, K.; Künkele, A.; Deubzer, H.E.; Schramm, A.; Sprüssel, A.; Thor, T.; Lindner, S.; Eggert, A.; Fischer, M.; Schulte, J.H. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. Oncotarget, 2017, 8(4), 6730-6741.
[22]
Tao, Y.F.; Li, Z.H.; Du, W.W.; Xu, L.X.; Ren, J.L.; Li, X.L.; Fang, F.; Xie, Y.; Li, M.; Qian, G.H.; Li, Y.H.; Li, Y.P.; Li, G.; Wu, Y.; Feng, X.; Wang, J.; He, W.Q.; Hu, S.Y.; Lu, J.; Pan, J. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation. Oncol. Rep., 2017, 37(3), 1419-1429.
[23]
Zhang, Z.; Zhang, G.; Kong, C. Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells. J. Cell. Mol. Med., 2017, 21(4), 758-767.
[24]
do Valle, Í.F.; Menichetti, G.; Simonetti, G.; Bruno, S.; Zironi, I.; Durso, D.F.; Mombach, J.C.M.; Martinelli, G.; Castellani, G.; Remondini, D. Network integration of multi-tumour omics data suggests novel targeting strategies. Nat. Commun., 2018, 9(1), 4514.
[25]
Keppner, S.; Proschak, E.; Kaufmann, M.; Strebhardt, K.; Schneider, G.; Spänkuch, B. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle, 2010, 9(4), 761-773.
[26]
Feng, Y.B.; Lin, D.C.; Shi, Z.Z.; Wang, X.C.; Shen, X.M.; Zhang, Y.; Du, X.L.; Luo, M.L.; Xu, X.; Han, Y.L.; Cai, Y.; Zhang, Z.Q.; Zhan, Q.M.; Wang, M.R. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int. J. Cancer, 2009, 124(3), 578-588.
[27]
Li, J.; Wang, R.; Kong, Y.; Broman, M.M.; Carlock, C.; Chen, L.; Li, Z.; Farah, E.; Ratliff, T.L.; Liu, X. Targeting Plk1 to enhance efficacy of olaparib in castration-resistant prostate cancer. Mol. Cancer Ther., 2017, 16(3), 469-479.
[28]
Roos, W.P.; Kaina, B. DNA damage-induced cell death by apoptosis. Trends Mol. Med., 2006, 12(9), 440-450.
[29]
Driscoll, D.L.; Chakravarty, A.; Bowman, D.; Shinde, V.; Lasky, K.; Shi, J.; Vos, T.; Stringer, B.; Amidon, B.; D’Amore, N.; Hyer, M.L. Plk1 inhibition causes post-mitotic DNA damage and senescence in a range of human tumor cell lines. PLoS One, 2014, 9(11)e111060
